Curium has announced a definitive agreement to merge with Lantheus Holdings Inc. in a transaction worth about $8 billion.
Curium is in advanced talks to acquire radiopharma company Lantheus Holdings Inc. in a deal that could be announced in the coming days.
US FDA approves Lantheus' brain-imaging agent for Alzheimer's assessment
Lantheus Holdings to Be Acquired for Initial $6.7 Billion
FDA Manufacturing Issues Delay Lantheus' Tumor Imaging Kit
US FDA declines to approve Lantheus' tumor imaging kit
Lantheus weighs potential $7 billion sale, Bloomberg News reports
These Analysts Raise Their Forecasts On Lantheus After Upbeat Q1 Results